Obsidio

Obsidio is a medical device manufacturer that describes itself as a pioneer in biomaterial platform technology providing minimally invasive blood vessel occlusion. In particular, the company is developing a hydrogel to block blood flow to the tumor

History

2022: Boston Scientific bought Obsidio

In mid-August 2022, Boston Scientific announced the purchase of Obsidio. The company did not disclose the value of the transaction.

Obsidio is developing a hydrogel technology capable of creating blood vessel blockade to slow or stop blood flow to a tumor or other abnormality. Obsidio's Gel Embolic Material (GEM) technology consists of a semi-solid hydrogel that is injected into blood vessels through a catheter. It is intended for use in the peripheral vascular system, that is, in veins through which blood enters the body in addition to the brain and heart, where its gel composition makes it easy to place and adapt to the structure of the patient's vessels.

Embolization procedures that prevent or completely block blood flow in the vein can be used to stop bleeding, stabilize malformations in the veins and arteries, and cut off tumors from the blood supply, leading to a decrease in their size. The ministry health care USA approved the Obsidio hydrogel in July 2022. It will be included in Boston Scientific's existing portfolio of devices and materials for interventional oncology and embolization.

After a tumultuous 2021, when Boston Scientific absorbed several small companies to the right and left, the medical giant's appetite for mergers and acquisitions appears to have slowed.

GEM technology combines the benefits of the embols available for August 2022, such as precise solid control and fluid compliance, to create a unique technology that ensures the effectiveness of procedures and more personalized therapy for patients, said Peter Pattison, president of the Boston Scientific Peripheral Interventions segment.

Neither company disclosed the financial terms of the acquisition, but Boston Scientific said it did not expect the purchase to have a material impact on its 2022 earnings.^[1]

Notes